The central nervous system (CNS) is the control panel of the body, which is responsible for cognition, movement, senses and emotions. Central nervous system diseases, is a group of neurological disorders that affect the structure or function of the brain or spinal cord, which collectively form the central nervous system (CNS). The CNS diseases include neurodegenerative diseases, neurodevelopmental diseases and traumatic injuries. Drugs such as analgesics, anesthetics, nervous system drugs and others are used in the treatment for these diseases.
The South Africa Central Nervous System (CNS) Therapeutic market is expected to reach US$ 3,686.91 Mn in 2027 from US$ 2,267.59 Mn in 2018. The market is estimated to grow with a CAGR of 5.6% from 2019-2027 from 2019-2027.
Request For Exclusive Sample PDF of this Report @ https://www.theinsightpartners.com/sample/TIPRE00004069/
Competitive Landscape Central Nervous System (CNS) Therapeutic Market:
The global central nervous system (CNS) therapeutic market is segmented on the basis of disease type, drug type and distribution channel. On the basis of disease type, the market is segmented as, neurovascular diseases, degenerative disorders, mental health, trauma and others. Based on drug type, the market is categorized as analgesics, nervous system drugs, anesthetics, Anti-Parkinson drugs, anti-epileptics and others. On the basis of distribution channel, the central nervous system (CNS) therapeutic market is segmented as, hospitals pharmacies and retail pharmacies.
Neurological disorders are very prevalent in Sub-Saharan Africa. The factors responsible for the growing burden include difficult perinatal situations, malnutrition, malaria, the human immunodeficiency virus & the acquired immune deficiency syndrome (HIV/AIDS), and demographic transitions. The primary neurological disorders include mental retardation, cerebral palsy, developmental disorders, epilepsy, peripheral neuropathy, stroke, trauma, and alcohol abuse. According to South African Pharmaceutical Journal in 2016, an estimated 818, 106 people are getting dementia per year, presently affecting more than 4 million people. The number is anticipated to be more than 14 million by 2050. Furthermore, HIV-associated dementia (HAD) is dominant in 15–30% of untreated adults with late-stage disease. The elderly patients, who previously have an increased risk of non-AIDS related dementias, are more prone to untreated HIV. Such a rising prevalence of CNS disorders is expected to create a demand for the central nervous system (CNS) therapeutic across the world.
South Africa Central Nervous System (CNS) Therapeutic market, based on drug type was segmented into analgesics, nervous system drugs, anesthetics, anti-parkinson drugs, anti-epileptics, others. In 2018, the analgesics segment held the largest share of the market, by drug type. This segment is also anticipated to grow at the highest rate during the forecast period because they are used to relive pain which provides relief to patients without being consciousness.
Reasons to Buy:
Interested in Purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00004069/
Note: If you have any special requirements, please let us know and we will offer you the report as you want.
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.